← All trials
NCT00142324
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2003
- Primary completion
- —
- Completion date
- Dec 1, 2005
- First posted
- —
- Last posted
- —
- Enrollment
- 190
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- Alzheimer's SocietyCollaborator
- University of LondonOverall official - principal investigator
- Kingshill Research Centre, Victoria Hospital, SwindonOverall official - principal investigator
- Moorgreen Hospital, SouthamptonOverall official - principal investigator
- University of LeicesterOverall official - principal investigator
- Queen Elizabeth Hospital NHS Foundation TrustOverall official - principal investigator
- University of ManchesterOverall official - principal investigator
- University of OxfordOverall official - principal investigator
- Medical Research CouncilCollaborator
- Newcastle UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.